Use of a Relapse Monitoring Board: An Independent Assessment for Determining Relapse in Clinical Trials for Bipolar Disorder

| October 30, 2011 | 0 Comments

by Norris Turner, PharmD, PhD; Wayne Macfadden, MD; Ravi Anand, MD; Sumant Khanna, MD, PhD; Mark H. Rapaport, MD; J. Thomas Haskins, PhD; Ibrahim Turkoz, MS; and Larry Alphs, MD, PhD  
Drs. Turner and Alphs are employees of Janssen Scientific Affairs, LLC, Titusville, New Jersey; Dr. Macfadden was an employee of Janssen Scientific Affairs, LLC,Titusville, New Jersey, at the time of this analysis; Dr. Anand is a consultant for Anand Pharma Consulting, St. Moritz, Switzerland; Dr. Khanna is a consultant affiliated with The Psychiatric Clinic, New Delhi, India; Dr. Rapaport is Chairman, Psychiatry and Behavioral Sciences, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, and Chief of Psychiatric Services, Emory Healthcare System, Atlanta, Georgia; Dr. Haskins was an employee of Johnson & Johnson Pharmaceutical Research and Development, LLC, Titusville, New Jersey, at the time of this analysis; and Mr. Turkoz is an employee of Johnson & Johnson Pharmaceutical Research and Development, LLC, Titusville, New Jersey.

Innov Clin Neurosci 2011;8(10):19–24

The content you are trying to view is restricted to registered members only.
Membership to Innovations in Clinical Neuroscience is free, so please consider becoming a member today.
Thank you
ICNS Online Editor
Please Login or Register for access.

Tags: ,

Category: Original Research, Psychiatry, Schizophrenia, Suicidality, Trial Methodology

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.